Sprycel gets FDA priority review for first-line CML, which is notable insofar as Tasigna is now approved in this indication (#msg-51437844): http://finance.yahoo.com/news/SPRYCEL-dasatinib-Receives-bw-1253115545.html?x=0&.v=1 The PDUFA date is 10/28/10.